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Available online at www.sciencedirect.comStructures of RT and its complexes combined with biochemical
and clinical data help in illuminating the molecular mechanisms
of different drug-resistance mutations. The NRTI drugs that are
used in combinations have different primary mutation sites. RT
mutations that confer resistance to one drug can be
hypersensitive to another RT drug. Structure of an RT-DNA–
nevirapine complex revealed how NNRTI binding forbids RT
from forming a polymerase competent complex. Collective
knowledge about various mechanisms of drug resistance by RT
has broader implications for understanding and targeting drug
resistance in general. In Part 1, we discussed the role of RT in
developing HIV-1 drug resistance, structural and functional
states of RT, and the nucleoside/nucleotide analog (NRTI) and
non-nucleoside (NNRTI) drugs used in treating HIV-1
infections. In this part, we discuss structural understanding of
various mechanisms by which RT confers antiviral drug
resistance.
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NRTI resistance by discrimination/exclusion
The dNTP substrates and analogs enter the open dNTP-
binding cleft (Figure 1a), and the correct dNTP is
selected for incorporation based on its complementarity
(Watson–Crick base pairing) with the template overhang
base (Figure 1b,c). The entire process starting from the
entry of dNTP to the incorporation of a nucleotide is
continuous and fast, although sorting of incorrectly paired
bases limits the rate of incorporation. An NRTI-TP
competes for RT binding with dNTPs; however, an
NRTI-TP does not inhibit dNTP binding, and usually
both bind RT at approximately micromolar affinity. HIV-
1 inhibition by an NRTI occurs primarily when the NRTI
is incorporated into the DNA primer. An NRTI-TP
usually has modifications of its deoxyribose part when
compared with a dNTP.www.sciencedirect.com A dNTP (or NRTI-TP) undergoes association and dis-
sociation of several molecular interactions with RT
through the path starting from dNTP recognition by
RT to nucleotide addition into a DNA primer strand.
In the process, the distinct structural features of an
NRTI-TP can be recognized by a specific mutation or
sets of mutations that discriminate the drug from the
analogous dNTP. For example, the active site mutation
M184V/I causes high-level resistance to 3TC and FTC. A
b-branched valine or isoleucine at the position 184 results
in steric hindrance with the b-L-pseudo-ribose ring and
thereby discriminates 3TC-TP (or FTC-TP) from dCTP
[1,2]. Both 3TC and FTC inhibit hepatitis B, and the
virus develops resistance to these drugs via analogous
mutations in hepatitis B polymerase [3]. The HIV-1 RT
mutation K65R emerges in response to treatments with
TDF, ABC, ddI or d4T [4–6], and the mutation occurs at
a higher frequency in subtype C HIV-1 [7]. The b3-b4
residue K65 interacts with the g-phosphate of a dNTP in
RT-DNA–dNTP ternary complex structures. Structures
of K65R RT-DNA–dATP (or TFV-DP) [8] revealed that
the guanidinium side-chain functionality introduced by
the K65R mutation stacks with the guanidinium group of
R72, a key conserved residue that is involved in dNTP
binding. The K65R-R72 guanidinium platform
(Figure 1d) helps discriminate TFV-DP from dATP.
Both wild-type and the mutant RT incorporated dATP
and dATP-a-S at a similar rate indicating no elemental
effect by K65R mutation, that is, the mutant RT dis-
criminates at a conformational step rather than at the
chemical step of NRTI incorporation [8].
The positioning of the sugar moiety of a dNTP/NRTI-
TP at the N site is primarily defined by its interactions
with amino acid residues R72, Y115, and Q151. The
conserved residue R72 helps dNTP binding by stacking
with the base and interacting with the a-phosphate. The
mutation Y115F emerged in response to ABC in mono- or
combination therapies [9]. The mutation Y115F in com-
bination with K65R decreases TDF susceptibility [10].
Residue Y115 is positioned underneath the sugar moiety
and supports dNTP binding (Figure 1d). The Y115F
mutation, which would retain its role in dNTP binding,
acquires the ability of NRTI discrimination; wild-type
hepatitis B polymerase has a phenylalanine at the equiv-
alent position [3]. RT mutation at a nearby position,
L74V, confers resistance to ddI [11,12]. Residue L74 is
positioned under the base of the first template overhang
and supports base-pair formation with an incoming dNTP
(Figure 1e). Modeling of the L74V mutation [8] suggests
that the mutation apparently weakens the templa-
te:dNTP base-pairing and/or causes repositioning ofCurrent Opinion in Virology 2013, 3:119–128
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NRTI-TP (or dNTP) binding and mechanisms of NRTI resistance. (a) Positioning of an AZTTP molecule in an open dNTP-binding cleft of RT
(represented by the electrostatic potential surface) in an RT-DNA complex [68]. (b) RT-DNA–dTTP polymerase complex before catalysis was
modeled using structural information from RT-DNA–dTTP complex [1], RT-ATP (a non-productive complex) [69], and RT-DNA–AZTTP complexes
[68]; the surrounding residues (cyan) can mutate to confer resistance to NRTIs. (c) A schematic representation of dNTP binding with the help of base-
pairing, base-stacking, interaction with RT, and metal chelation; the catalytic reaction of DNA polymerization proceeds with an octahedral coordination
environment for two Mg2+ ions. (d) An active-site superposition of K65R RT-DNA–dATP [8] and EEM RT-DNA–AZTppppA complexes [23] shows the
relative locations of three distinct sites that confer resistance to three classes of NRTIs (3TC/FTC, TDF, and AZT). The 3TC-resistance mutation
introduces a b-branch, TDF-resistance mutation K65R forms the K65R-R72 guanidinium platform, and primary EEMs T215Y and K70R help binding of
an ATP molecule as the excision agent; mutations at one site, in general, are incompatible with mutations at the other two sites which provides a partial
structural/biochemical basis for synergy between NRTIs. (e) Molecular surface representing the support to template–dNTP base pair provided by R72
and L74 side-chains. (f) An L74V mutation would disrupt the platform, and the mutation is incompatible with the K65R induced K65R + R72 part of the
platform. (g) A schematic representation of catalytic reaction of polymerization versus excision by HIV-1 RT [23]. (h) Binding of AZTppppA, the ATP-
mediated excision product of AZTMP, to HIV-1 RT (shown as green molecular surface) in complex with DNA [23].dNTP by reducing the support to the template base
(Figure 1f).
Residue Q151 interacts with the guanidinium group of
R72 [8]. The fact that the Q151 side chain in wild-type
RT is unable to discriminate between a dNTP and a
dideoxynucleoside-TP suggests that there may not be aCurrent Opinion in Virology 2013, 3:119–128 stable interaction between Q151 and the 30-OH of a
dNTP. In contrast, Q151M mutation can cause resistance
to dideoxynucleoside drugs. Q151M and four mutations
(A62V, V75I, F77L, and F116Y), known as the ‘Q151M
complex,’ co-emerged as a set in response to AZT com-
bined with dideoxynucleoside drugs [13,14]. The Q151M
complex causes resistance to almost all NRTIs exceptwww.sciencedirect.com
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mutations are termed multidrug-resistant (MDR) viruses.
The specific structural basis of NRTI resistance caused
by Q151M or Q151M complex RT has not been charac-
terized; however, it has been shown biochemically that
Q151M mutation discriminates NRTI-TPs [15–17], and
the accompanying four mutations in the Q151M complex
enhance the discrimination ability and viral fitness
[13,18]. RTs carrying Q151M mutation develop resist-
ance by discriminating NRTI-TPs from dNTPs before
incorporation [19].
NRTI resistance by excision
A set of RT mutations (M41L, D67N, K70R, L210W,
T215Y, and K219Q), known as thymidine analog
mutations (TAMs) or AZT-resistance mutations (AZTr)
[20], emerged in patients as distinctive mutations leading
to AZT resistance [20]. Later, these mutations were
biochemically shown to help excise AZT after the drug
was incorporated into the DNA primer [21,22]. Excision
is the primary mechanism by which RT develops resist-
ance to AZT. Subsequently, several additional mutations
were found to assist excision of AZT or other NRTIs, and
this list of mutations can be grouped as Excision Enhan-
cing Mutations (EEMs) [23]. RT has the ability to
excise either a normal nucleotide or an NRTI from the
30-end of a DNA primer by pyrophosphorolysis, a reverse
reaction of DNA polymerization (Figure 1g). Wild-type
RT can excise the primer terminal nucleotide using a
pyrophosphate or an ATP molecule as the excision agent;
however, an RT carrying EEMs (TAMs) has a signifi-
cantly enhanced excision ability using cellular ATP
molecules as the excision agent [24,25]. The mutations
facilitate ATP-dependent excision, generating
AZTppppA (Figure 1g) as the reaction product. Crystal
structures of RT-DNA–AZTppppA and related com-
plexes illuminate the molecular mechanism of ATP-
mediated excision of AZT (Figure 1g,h) [23,26]. In
agreement with an earlier hypothesis [25], the RT-
DNA–AZTppppA structures revealed that the mutations
help create an ATP-binding pocket adjacent to the
dNTP-binding cleft. The T215Y mutated aromatic side
chain stacks with the base while the K70R mutated side
chain forms polar interactions with the a-phosphate and
30-OH of ATP. The structural information revealed that
the primary AZT-resistance mutations K70R and T215Y
[27,28] play the most significant roles in ATP binding.
The b-g-diphosphate moiety of ATP mimics a pyropho-
sphate that chelates the two active site Mg2+ ions and
triggers pyrophosphorolysis by RT to remove AZT-MP
from the DNA primer terminus. The mutation-induced
pocket has the potential to bind all NTPs and dNTPs;
however, ATP is primarily used as the excision agent in
vivo because: firstly, pyrophosphate is present at rela-
tively low concentration in a cell; secondly, a dNTP
would favor binding at the N site to form a polymerase
catalytic complex rather than an excision complex;www.sciencedirect.com thirdly, an NTP with a purine base would have more
extensive stacking with T215Y than one with a pyrimi-
dine base; GTP was also shown to be an efficient excision
substrate [22]; and fourthly, the cellular concentration of
ATP is about a order magnitude higher than that of GTP
[29]. The remaining EEMs play supportive roles in
enhancing excision and improving viral fitness on top
of the primary EEM backgrounds [23,30,31]. The
mutations D67N, and K219Q [32–34] arise on top of
the K70R background, whereas M41L and L210W
mutations are associated with T215Y mutation [35,36].
The T69 insertions in the b3–b4 fingers loop in combi-
nation with TAMs allow RT to excise a broader range of
NRTIs [37–40]. Also, RT containing the D67 deletion
enhances ATP-mediated excision of AZT on top of the
TAM background [41,42]; however, the D67 RT does not
excise a wider range of NRTIs.
In a fascinating parallel development, the hepatitis C
(HCV) virus RNA-directed RNA polymerase (NS5B) has
been shown to be capable of catalyzing NTP-mediated
nucleotide excision [43,44]. Analogous to the NTP-
mediated nucleotide excision reaction by HIV-1 RT, that
produces a dinucleoside tetraphosphate, the excision
product by HCV NS5B (RNA polymerase) has ribonu-
cleosides on both ends. Using a kinetic study, Jin et al.
described that HCV polymerase excises chain-termin-
ators and mismatched NMPs from 30-end of a growing
RNA primer [44]. This result suggests that HCV and
other polymerases may be using excision as a general
fidelity mechanism. A lower rate of misincorporation by
HIV-1 RT in vivo than free RT, as discussed in Part 1,
may indicate that RT in infected cell conceivably may be
using excision to enhance fidelity.
Cooperative/antagonistic mutations and NRTI
combinations in therapy
In general, members of a class of inhibitors such as
NNRTIs or PIs, that share a common binding site and
mode of inhibition, do not show synergistic inhibition if
combined. In contrast, many combinations of NRTIs
have synergistic impact in inhibiting HIV-1 in patients.
The NRTI synergies were found empirically from vir-
ological investigations and from clinical data; however,
effective modeling and analysis of empirical data
[45,46], and biochemical and structural studies help
in understanding the complex synergistic relationships
and their molecular basis. From a simplified structural and
biochemical perspective, a synergistic relationship be-
tween two NRTI drugs can be influenced by the antagon-
istic relationship among the primary resistance mutations
to the NRTIs. Primary NRTI-resistance exclusion
mutations appear along the dNTP-binding track, or
EEMs emerge at sites adjacent to the dNTP-binding
track to facilitate excision. The sites and molecular
mechanisms of resistance to one subclass of NRTIs are
different than those to another subclass of NRTIs [8];Current Opinion in Virology 2013, 3:119–128
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TDF, and AZT (Figure 1d). Resistance mutations to one
subclass of NRTI can be positively or negatively associ-
ated with the resistance mutations to another subclass.
The K65R + M184V double mutant is primarily detected
in patients treated with a TDF, 3TC, and ABC combi-
nation [47]. The double mutant has increased resistance
to 3TC and FTC, decreased rate of nucleotide incorp-
oration, and increased susceptibility to TDF [17,48]. The
b-branch introduced by the M184V mutation, and the
K65R-induced R72-K65R guanidinium platform, form
two walls on either side of the sugar moiety of a
dNTP/NRTI-TP at the N site (Figure 1d). Thereby,
the K65R + M184V mutations create structural con-
straints [8] that firstly, still can accommodate the com-
pact acyclic methoxypropyl moiety of TFV-DP, secondly,
add restraint to dNTP binding that would slow down
nucleotide incorporation, and thirdly, are highly discri-
minatory against the b-L-pseudo-ribose ring of 3TC (or
FTC)-TP. Even though both K65R and M184V are
exclusion mutations that co-emerge, a lower replication
fitness and increased susceptibility to TDF may account
for the clinical benefit of combining TDF and 3TC (or
FTC).
Among other exclusion mutations, K65R is negatively
associated with L74V [49,50] or most EEMs [51], and the
combinations emerge less frequently. The mutations
K65R and L74V are incompatible because the K65R-
R72 platform and L74V-modified surface do not provide
optimal structural support to dNTP-template base pair-
ing [8] (Figure 1e,f); K65R + L74V double mutant RT
has a significantly reduced rate of nucleotide incorpora-
tion [49]. Also, L74V mutation decreases AZT excision
[11,52]; probably by perturbing the positioning of AZT (at
the DNA primer end) at the N site even when EEMs
facilitate ATP binding. The multidrug-resistant Q151M
complex in association with other exclusion mutations
K65R or K70T/S/Q increases resistance to TDF while
remaining resistant to dideoxynucleosides [53,54].
In general, exclusion mutations and EEMs are antagon-
istic [55–57]. Structurally, the K65R + R72 platform
would interfere with proper positioning of the b-g-pyr-
ophosphate moiety of ATP, which is essential for excision
[8] (Figure 1d). Similarly, K70R and K65R would perturb
the positioning of the triphosphate moiety of a dNTP and
interfere with polymerization. Unlike the EEM K70R, all
other mutations K70E/Q/S/T at position 70 function as
exclusion mutations because these mutated side chains
would not help ATP binding; however, the mutations
may reposition or sense the g-phosphate of an incoming
NRTI-TP differently from that of a dNTP and invoke
NRTI resistance by an exclusion mechanism. The
mutation K70E is also antagonistic with EEMs [58],
because the negatively charged shorter side chain of
K70E is likely to interfere with the binding or positioningCurrent Opinion in Virology 2013, 3:119–128 of ATP (Figure 1d,h). M184V/I mutation is antagonistic
with excision. M184V/I mutation, which reduces the
binding of 3TC (or FTC) at the N site, also may hinder
the positioning of an NRTI-terminated 30 end of a DNA
primer at the N site for excision, that is, 3TC resistance
enhances AZT susceptibility which favors the synergistic
impact of combining AZT and 3TC [59].
RT inhibition by NNRTIs
RT inhibition by NNRTIs is indirect. Early structures of
RT and RT-NNRTI complexes showed that NNRTI
binding traps RT in a rigid conformational state with an
open nucleic acid-binding cleft; however, the impact of
NNRTI binding on the binding of nucleic acid or dNTP,
and above all, the mechanism of NNRTI inhibition of
DNA polymerization remained elusive. Pre-steady-state
and steady-state kinetic experiments in the mid-1990s
suggested that the binding of an NNRTI inhibits the
chemical step of DNA polymerization while dsDNA and
dNTP remain bound to RT [60,61]. A single-molecule
FRET study revealed that RT frequently flips and slides
over a double-stranded nucleic acid substrate [62,63];
binding of dNTP stabilized the RT-DNA complex in a
polymerase-competent mode while binding of an
NNRTI induced destabilizing effects causing increased
dissociation/association of RT with a double-stranded
nucleic acid. The postulated mechanisms of inhibition
by an NNRTI were: firstly, restriction of thumb mobility
[64], secondly, distortion of the catalytic triad [65] that
would block the chemical step of DNA polymerization by
RT [60], thirdly, blockage of conformational state tran-
sition and not the chemical step leading to nucleotide
incorporation [66], fourthly, repositioning of the primer
grip [67], and fifthly, loosening of the thumb and fingers
clamp [62]. Multiple mechanistic hypotheses evolved
because NNRTI binding causes multiple structural and
conformational changes in RT, and the direct and indirect
contributions of individual changes toward the NNRTI
inhibition were not clear.
The hinge motion between the thumb and palm is
essential for the translocation of RT along the nucleic
acid following each nucleotide incorporation. The breath-
ing space that is transiently created traps an NNRTI.
Upon binding of an NNRTI, RT loses its conformational
mobility to carry out nucleotide addition and transloca-
tion. The NNRTI pocket does not exist in any RT
structure that does not contain a bound NNRTI. A direct
consequence of NNRTI binding is the opening of the
NNRTI pocket to accommodate the inhibitor. The
pocket formation requires the b12–b13–b14 sheet, which
contains the ‘primer grip’, to move away from the b6–
b10–b9 sheet which contains the catalytic triad (D110,
D185, and D186). The recent structure of RT-DNA–
nevirapine complex provides a snapshot of the effects of
an NNRTI on DNA polymerization [68] (Figure 2a,b).
The binding of nevirapine shifts the primer grip whichwww.sciencedirect.com
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Structural basis for the inhibition of DNA polymerization by an NNRTI. (a) Structure of RT-DNA–AZTTP ternary complex obtained by soaking AZTTP
into crystals of RT-DNA complex. (b) Soaking of nevirapine into the crystal created the NNRTI pocket, repositioning the ‘primer grip’ (on the b12–b13–
b14 sheet) that moved the primer terminus away from the polymerase active site. (c) Electrostatic potential surface of RT bound to DNA and
nevirapine. The crystallization experiments and structures showed an open dNTP-binding cleft into which dNTPs/NRTI-TPs can enter; however,
structural perturbation by NNRTI binding did not allow a dNTP to chelate metals and form base-pairing and base-stacking interactions. (d) These
structural constraints preclude the formation of an RT-DNA–dNTP polymerase competent (P) complex, rather forms a non-productive (P0) complex in
the presence of an NNRTI — a structural basis for NNRTI inhibition [68].concomitantly displaces the primer 30-end by 5.5 A˚
away from its position at the polymerase active site.
The interaction between the template-primer and the
polymerase domain of RT is decreased upon nevirapine
binding, which correlates with the earlier observation by a
single-molecule study [62]. The fingers subdomain has
an open conformation that would allow the entry of
dNTPs (Figure 2c); however, the repositioned tem-
plate-primer would not permit the base-pairing or base-
stacking to support the binding of a dNTP (Figure 1c) atwww.sciencedirect.com the N site. This appears to be a primary reason why
ordered binding of dNTP (or analog) to an RT-DNA
complex was not observed in the presence of nevirapine
whereas RT-DNA–dNTP (or analog) complexes could
be formed when no NNRTI was present [68]. These
experiments were carried out in crystals that permitted
rearrangements of the polymerase domain upon binding
of a dNTP/analog or an NNRTI. Our attempts to form an
RT-DNA–nevirapine–AZTTP complex yielded the
structure of only RT-DNA–nevirapine complex, andCurrent Opinion in Virology 2013, 3:119–128
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active site when nevirapine is bound to RT [68]. The
structural information and published biochemical/bio-
physical results suggest that dNTPs may enter the
dNTP-binding cleft (Figure 2c), interact with RT, and
may induce conformational changes of RT like closing of
the fingers; however, formation of a catalytically relevant
RT-DNA–dNTP complex [1] would not be permitted
when an NNRTI is bound. The repositioning of the
template-primer by nevirapine binding disfavors the
base-pairing or base-stacking of a dNTP at the N site.
In addition to the base-pairing and base-stacking, metal
chelation at the active site also contributes toward the
binding of a dNTP substrate in a catalytically competent
RT-DNA–dNTP complex (Figure 1b,c). None of the
structures of RT-NNRTI binary complexes or the RT-
DNA–nevirapine complex had any metal ion present at
the polymerase active site, suggesting that a potential
distortion of the catalytic site [65,69] by an NNRTI also
forbids ordered binding of the triphosphate moiety of a
dNTP because of the loss of Mg2+ ion chelation at the
active site. Thereby, NNRTI binding prevents RT from
achieving a conformational state of RT-DNA (or RT-
DNA/RNA) complexed with dNTP that would be
required for catalysis [66]. Additionally, the structure of
RT-DNA–nevirapine complex showed that the thumb
restriction [64] is induced by the primer grip reposition-
ing, and the thumb and fingers clamp is loosened [62] by
the reduced interactions between the polymerase domain
of RT and DNA. All of these effects of NNRTI binding
force RT into a structurally and catalytically non-compe-
tent complex for dNTP binding at the N site and for
polymerization (Figure 2d).
NNRTI resistance
Almost all of the NNRTI-binding pocket residues can
mutate, and most of the mutations can confer resistance to
NNRTIs. Some of the observed NNRTI-resistance
mutations are L100I, K101E, V106A, K103N, V179D,
Y181C, Y188L, G190A, and E138K (p51); K103N and
Y181C are the most commonly observed mutations in
patients exposed to NNRTI treatments. Residues K101,
K103, and E138 (p51) are located at the rim of the pocket
entrance for most NNRTIs. The remaining residues
directly interact with an NNRTI in the pocket. The
pocket mutations can cause firstly, loss of aromatic ring
stacking interactions (Y181C or Y188L), secondly, steric
hindrance (L100I or G190A/S), and thirdly, alteration of
hydrophobic interactions (V106A or V179D). Impacts of
NNRTI-pocket alteration are relatively severe on the
rigid first-generation NNRTIs, for example, high level of
resistance by Y181C to nevirapine. Substitution of G190
fills the central part of the pocket by which mutations at
position 190 would reduce the binding of most NNRTIs;
however, larger substitutions like G190E/Q severely
impair the replication capacity of RT [70,71]; G190A is
the most frequently observed mutation at position 190Current Opinion in Virology 2013, 3:119–128 because G190A mutation has the least impact on RT
polymerase activity. A large side chain at position 190
would partly occupy the NNRTI-binding pocket and
could conceivably function as a pseudo-NNRTI in redu-
cing RT activity. A fitness cost is associated with certain
pocket mutations or combinations of mutations if the
virus has to develop resistance to more effective
NNRTIs. Such NNRTIs will have to remain potent
against all common NNRTI-resistance mutations that
have minimum adverse impact on the viral replication.
Rim mutations at K101, K103, or E138 (p51) generally do
not alter the bound states of NNRTIs. Two recent
clinical studies showed that K103N and E138K mutations
are predominantly associated with treatment failure of the
efavirenz and rilpivirine, respectively, when combined
with TDF and FTC [72,73]; M184V was the NRTI-
resistance mutation that co-emerged in both arms of the
study. The study indicated a comparable response by
25 mg/day of rilpivirine or 600 mg/day of efavirenz; rilpi-
virine was better tolerated, yet had a higher rate of vir-
ological failure. Efavirenz is the most widely used NNRTI,
and K103N is the characteristic clinical resistance mutation
that emerged upon treatments with efavirenz. In fact, the
K103N mutation confers an almost uniform level of cross-
resistance to most NNRTIs. In crystal structures of wild-
type RT, the K103 side chain points outward and does not
interact with a bound NNRTI. The K103N mutation
apparently restricts access to the pocket for most NNRTIs.
In absence of an NNRTI, the shrunken pocket accom-
modated a water molecule [74], whereas the K103N/
Y181C mutant RT apo structure revealed that the solvent
molecule was replaced by a sodium ion that had a distorted
octahedral coordination involving the side chains of N103
and Y188, and the main-chain carbonyl oxygen of K101 and
amide group of N103 [69]; the side chains of N103 and
Y188 were also in position to make a hydrogen-bonding
interaction. The difference in the energetic cost required
for pocket formation by displacing the secluded water
versus ion, or the extra hydrogen bond, may contribute
to NNRTI resistance; however, the exact mechanism by
which the K103N mutation develops resistance remains
unclear. In rilpivirine, which remains effective against
K103N mutation, the central pyrimidine ring interacts
with the side chain of N103 [75]. A computational study
using Monte Carlo/free energy perturbation calculations
had suggested that NNRTIs that would form water-
mediated hydrogen bonds at the entrance to the pocket,
in particular with E138 (p51), would retain potency against
K103N mutation [76].
The rim mutations K101E or E138K (p51) appear to have
effects on NNRTI binding analogous to that of K103N.
In wild-type RT, the side chains of E138 (p51) and K101
form a hydrogen bond that is lost in E138K or K101E
mutant RTs [77]; the loss of the hydrogen bond was
assumed to be the primary cause of NNRTI resistancewww.sciencedirect.com
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E138K and K101E would restore the hydrogen bond
between the two residues, and the double mutant RT
would restore efficacy of NNRTIs. However, the double
mutant showed a high level of NNRTI resistance and the
E138D mutant RT that would not form the hydrogen bond
with K101 remained NNRTI-susceptible just by retaining
the charge of E/D138 side chain [78], which downweighs
the suggested critical role of the hydrogen bond between
K101 and E138 on NNRTI binding. A recent kinetic study
indicated that rilpivirine had a higher rate of dissociation
from E138K (p51) mutant versus wild-type RT [79]. The
cumulative biochemical and structural knowledge so far
indicates that the rim mutations K103N and E138K prim-
arily alter the association and dissociation of NNRTIs with
RT. Even though E138K itself only causes a low level of
resistance to rilpivirine, addition of M184V/I mutation
enhances rilpivirine resistance, and E138K enhances the
fitness of the virus on the M184V/I background, which
reveals a synergistic relationship between the NNRTI-
and NRTI-resistance mutations that benefits the virus
[72]. In contrary, the NNRTI-resistance mutation
Y181C on a background of NRTI-resistance mutations
decreases ATP binding as the excision substrate [80],
indicating an antagonistic relationship.
Use of NRTIs and NNRTIs in combinations
Effective combinations of HIV-1 drugs are being opti-
mized empirically based on clinical data. One or more
NRTIs are used in almost all current clinical drug cock-
tails, and many combinations of NRTIs are synergistic.
RT mutations that emerge along the dNTP-binding cleft
to discriminate NRTI-TPs or to enhance excision of an
NRTI are often incompatible for RT fitness, or mutations
that develop resistance to one NRTI enhance sensitivity
to another – among the molecular bases for the long-term
clinical utility of NRTIs in combinations. Because of the
different inhibition mechanisms, combinations of
NNRTIs and NRTIs are effective in reducing viral
replication. NNRTIs have the advantage of high speci-
ficity and consequently low side effects. An NNRTI is
primarily used in combination with NRTI(s) in first-line
therapies against HIV-1 infections; however, higher level
of treatment failure has been observed for patients carry-
ing traces of NNRTI-resistance mutations [81].
NNRTIs are also important for blocking mother-to-child
transmission, and NNRTIs are currently under clinical
investigations as potential microbicides to prevent sexual
transmission of HIV-1 [82]. The relationships among RT
mutations are complex and are still evolving [46]. New
resistance patterns [83,84] emerge with the use of new
drugs and combinations. No single experimental
approach or analysis fully explains the complex phenom-
ena associated with HIV-1 infection and drug resistance.
Multiple experimental platforms, analysis of experimen-
tal data across the platforms, and their relationships with
clinical observations are continually helping to unfoldwww.sciencedirect.com new details on the virus and antiviral resistance. Frequent
evolution of new resistance mutation patterns and emer-
ging side effects from long-term use of drugs underscore
the constant need for new HIV-1 drugs.
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